Syra Health Q3 2026 earnings

SYRA · 2026-11-03 09:29 BMO ET · 8-K on SEC

Record revenue of $2.6 million and a 46.3% gross margin, the highest in history, with net income of $344,610.

Headline numbers

MetricActualYoYQoQ8-K location
Revenue$2.6 million+52%+8%Ex. 99.1, income statement
EPS (GAAP)$0.02+$0.040.00Ex. 99.1, income statement
Net income$344,610+$570,512+$94,368Ex. 99.1, income statement
Adj. EBITDA$301,725+$520,326+$48,525Ex. 99.1, income statement
Adj. EBITDA margin46.3%+13.4 pp+1.8 ppEx. 99.1, income statement

Revenue breakdown

SegmentActualYoYShare of revenueNote
Population health solutions$1.9 million+52%76%Led growth
Healthcare workforce$613,507+50%24%Prioritized better-margin contracts

Margins and costs

  • Gross margin 46.3% (prior 32.9%, change +13.4 pp)
  • Operating expenses $885,039 (+12% YoY)
  • One-offs in the quarter Provision for income taxes of $44,953; Depreciation expense decreased 87% to $715
  • Effective tax rate 13% (prior-year 0%, year-to-date 13%)
  • Non-GAAP bridge EBITDA (Earnings before Interest, Taxes Depreciation and Amortization)

KPIs

MetricActualPrior quarterPrior yearChange
Cash and cash equivalents$2.4 million$2.1 million$1.6 million+$300,000
Net cash provided by operating activities (9 months)$975,023$643,183-$158,554+$1.1 million
Total assets$4.2 million$3.8 million$2.8 million+$400,000

Guidance

MetricGuidePrior guideChange
Full-year profitabilityOn track to achievePreviously stated goal of full-year profitability in 2026Maintained

What drove it

  • Revenue story Population health solutions grew 52% to $1.9 million; healthcare workforce grew 50% to $613,507.
  • EPS story EPS improved to $0.02 from a loss of $(0.02) in Q3 2025.
  • One-off check Provision for income taxes of $44,953; depreciation expense of $715.

The good

  • Record quarterly revenue of $2.6 million
  • Highest gross margin in history at 46.3%
  • Third consecutive profitable quarter with net income of $344,610

The bad

  • none

The ugly

  • none

Open questions

  • The filing does not disclose the specific percentage of revenue growth attributed to the CMS ACCESS Model approval.
  • The filing does not disclose the specific impact of the Syrenity Enterprise build-out on R&D expenses.
Full release

Syra Health (SYRA) earnings release, November 3, 2026

Syra Health Corp (SYRA) · Form 8-K, Item 2.02 · Filed · SEC filing

Exhibit

99.1

Syra

Health Delivers Third Consecutive Profitable Quarter: Record Revenue of $2.6 Million, Up 52%, and 46.3% Gross Margin

Carmel,

Ind., November 3, 2026 /

PRNewswire – Syra Health Corp. (OTCQB: SYRA) (“Syra Health” or the “Company”), an integrated healthcare solutions company powering better health outcomes through prevention-focused, accessible, and affordable solutions, announced today its financial results for the third quarter ended September 30, 2026.

Q3

2026 Financial Highlights

Syra

Health extended its profitability in Q3 2026, reporting net income of $344,610 compared with a net loss of $(225,902) in Q3 2025, a year-over-year improvement of $570,512.

Revenue for the quarter ended September 30, 2026, climbed 52% to a record $2.6 million, the highest quarterly revenue in the Company’s history, up from $1.7 million in the prior-year period.

With revenue growing faster than costs, gross margin widened by approximately 1,340 basis points to 46.3%, up from 32.9% a year earlier. The result sets a new Company record, surpassing the previous high of 44.5% achieved just last quarter.

EPS rose to $0.02 from a loss of $(0.02) in Q3 2025, a year-over-year improvement of $0.04 per share.

EBITDA improved by $520,326 or 238.03% to $301,725 in Q3 2026, compared with a loss of $(218,601) in Q3 2025.

Year-to-date results reinforce the strength of the business. For the nine months ended September 30, 2026, Syra Health generated net income of $ 835,831 compared with a net loss of $(761,763) a year earlier, while net cash provided by operating activities reached $975,023, compared with net cash used by operating activities of $(158,554) in the prior-year period.

2026

Financial Outlook

With three consecutive profitable quarters now behind us, Syra Health remains on track to achieve its previously stated goal of full-year profitability in 2026. Given the RFP- and contract-driven nature of its business, the Company continues to expect the timing of awards, revenue recognition, and contract milestones to cause some quarter-to-quarter variability.

Recent

Operational Highlights

Management

Commentary

Greg

Alexander, CEO of Syra Health, said, “Q3 2026 marks our third consecutive profitable quarter, and it is the clearest evidence yet that Syra Health has become a profitable growth company. We grew revenue 52% year-over-year to a record $2.6 million, and we did it profitably: gross margin reached 46.3%, the highest in our history, up more than 13 percentage points from a year ago. That kind of growth paired with that kind of margin expansion doesn’t happen by accident. It reflects deliberate choices we have made to focus on our high-value population health solutions, pursue better-margin workforce contracts, and run the business with discipline.

The results speak to the durability of what we’re building. Through the first nine months of 2026, we generated net income of $835,831 compared with a loss of $(761,763) in the same period last year, produced $975,023 in operating cash flow, and ended the quarter with

$2.4 million in cash and no long-term debt. We are funding our own growth, including continued investment in Syrenity Enterprise, our

B2B mental and behavioral health solution.

We believe the best is still ahead. Our approval for Syrenity within the CMS ACCESS Model with our partner HealthSync is expected to become a consistent source of revenue over the next decade. With strong momentum across our business, we remain focused on delivering full-year profitability in 2026 and creating long-term value for our customers, the communities we serve, and our shareholders.”

Q3

2026 Financial Results

Third quarter 2026 revenue rose 52% to $2,557,295, up from $1,687,971 in the third quarter of 2025. The Company’s high-margin population health solutions continued to lead the way, also growing 52% year-over-year to $1,943,788 from $1,280,011 in the same period of 2025.

Healthcare workforce revenue increased 50% to $613,507 from $407,960 a year earlier as Syra Health met rising demand for solutions that address critical healthcare workforce shortages while prioritizing contracts with stronger margins.

Gross profit margin widened by 1,340 basis points to 46.3% in the third quarter of 2026, up from 32.9% in the prior year period, driven by a favorable revenue mix and ongoing operating leverage.

The

Company balanced disciplined cost management with targeted investment in growth. Salaries and benefits grew to $440,172 in Q3 2026 from

$336,390 in the prior-year period as Syra Health added talent to support its expansion. Professional services fell 9% to $175,295 in

Q3 2026 from $191,726 in Q3 2025, and selling, general and administrative expenses declined 12% to $222,141 from $252,384 in the prior-year period. Research and development expenses increased to $46,716 in Q3 2026 from $816 in Q3 2025, funding the build-out of Syrenity Enterprise, the Company’s B2B mental and behavioral health solution. Depreciation expense dropped 87% to $715 from $5,396 a year earlier.

Operating activities provided $975,023, in net cash for the nine months ended September 30, 2026 compared with $(158,554) in the prior-year period.

Cash and cash equivalents grew to $2.4 million as of September 30, 2026, from $1.6 million as of December 31, 2025, with no long-term debt.

SYRA

HEALTH CORP.

BALANCE

SHEETS

SYRA

HEALTH CORP.

STATEMENTS

OF OPERATIONS

(Unaudited)

SYRA

HEALTH CORP.

STATEMENTS

OF CASH FLOWS

(Unaudited)

Non-GAAP

Financial Measures

In addition to financial results reported in accordance with accounting principles generally accepted in the United States of America (“GAAP”),... (truncated)non-GAAP financial measures internally to facilitate period-to-period comparisons and analysis of our operating performance and liquidity and believe it is useful to investors as a supplement to GAAP measures in analyzing, trending, and benchmarking the performance and value of our business. However, this measure is not intended to be a substitute for those reported in accordance with GAAP. These measures may be different from non-GAAP financial measures used by other companies, even when similar terms are used to identify such measures.

For reconciliations of historical non-GAAP financial measures to the most comparable financial measures under GAAP, see the table below.

About

Syra Health

Syra

Health is an integrated healthcare solutions company helping government and commercial healthcare organizations improve health outcomes through prevention, expanded access, and affordable care. Our population health analytics turn data into proactive, actionable intelligence, and our public health community needs assessments help health departments direct resources where communities need them most. In mental and behavioral health, Syra Health’s award-winning Syrenity Enterprise solution and SyraBot, a HIPAA-compliant and ADA-accessible

AI chatbot, deliver secure, accessible support in highly regulated environments. Syra Health also provides healthcare staffing, training, and education designed to help organizations reduce costs, strengthen their workforce, and deliver consistent, high-quality care.

Discover our healthcare solutions at www.syrahealth.com and follow the Company on

LinkedIn.

Forward-Looking

Statements

Financial statements

Income Statement

For the Three Months Ended — (Unaudited)

For the Three Months Ended – 2026For the Three Months Ended – 2025For the Nine Months Ended – 2026For the Nine Months Ended – 2025
Net revenues2,557,2951,687,9717,225,2385,491,944
Cost of services1,372,2541,133,4304,002,6393,595,352
Gross profit1,185,041554,5413,222,5991,896,592
Operating expenses:
Salaries and benefits440,172336,3901,204,4171,169,951
Professional services175,295191,726500,455580,691
Research and development expenses46,716816100,98867,701
Selling, general and administrative expenses222,141252,384671,673828,741
Depreciation7155,3962,51018,171
Total operating expenses885,039786,7122,480,0432,665,255
Operating income (loss)300,002-232,171742,556-768,663
Other income (expense):
Interest income1,0088,17454,35415,892
Provision for income taxes44,95344,953
Interest expense-1,353-1,905-6,032-8,992
Total other income (expense)44,6086,26993,2756,900
Net income (loss)344,610-225,902835,831-761,763
Weighted average common shares outstanding - basic14,194,48211,939,16913,111,28911,823,089
Weighted average common shares outstanding - diluted15,142,24711,939,16914,059,05411,823,089
Net income (loss) per common share - basic and diluted0.02-0.020.06-0.06

Income Statement

Nine Months Ended

Nine Months Ended – September 30, 2026Nine Months Ended – September 30, 2025
Net Income (Loss)835,831-761,763
Interest expense6,0328,992
Depreciation expense2,51018,171
Provision for income taxes-44,953
Earnings before Interest, Taxes Depreciation and Amortization799,420-734,600

Income Statement

Three Months Ended

Three Months Ended – September 30, 2026Three Months Ended – September 30, 2025
Net Income (Loss)344,610-225,902
Interest expense1,3531,905
Depreciation expense7155,396
Provision for income taxes-44,953
Earnings before Interest, Taxes Depreciation and Amortization301,725-218,601

Balance Sheet

September 30, — BALANCE SHEETS

September 30, – 2026 – (Unaudited)December 31, – 2025
Current assets:
Cash and cash equivalents2,383,4131,614,733
Accounts receivable, net1,517,493918,374
Other current assets262,998205,423
Total current assets4,163,9042,738,530
Property and equipment, net4,4766,986
Right-of-use asset57,01027,401
Total assets4,225,3902,772,917
Current liabilities:
Accounts payable211,169247,520
Accounts payable, related party125,00072,000
Accrued expenses367,996194,821
Deferred revenue261,24916,611
Current portion of operating lease liability, related party57,01027,401
Notes payable179,272116,386
Total current liabilities1,201,696674,739
Total liabilities1,201,696674,739
Stockholders’ equity:
Class A common stock, $0.001 par value, 100,000,000 shares authorized, 13,850,279 and 11,339,169 shares issued and outstanding, respectively13,85011,339
Convertible class B common stock, $0.001 par value, 5,000,000 shares authorized, 350,000 and 600,000 shares issued and outstanding, respectively350600
Additional paid-in capital11,894,18911,806,765
Accumulated deficit-8,884,695-9,720,526
Total stockholders’ equity3,023,6942,098,178
Total liabilities and stockholders’ equity4,225,3902,772,917

Cash Flow

For the Nine Months Ended — (Unaudited)

For the Nine Months Ended – September 30, – 2026For the Nine Months Ended – September 30, – 2025
CASH FLOWS FROM OPERATING ACTIVITIES
Net income (loss)835,831-761,763
Adjustments to reconcile net income (loss) to net cash provided by operating activities:
Depreciation2,51118,171
Common stock issued for services2,586
Stock-based compensation89,68575,194
Changes in operating assets and liabilities:
Accounts receivable-599,119-245,428
Other current assets211,654279,890
Right-of-use asset50,51189,621
Accounts payable-36,352215,723
Accounts payable, related party53,000137,764
Deferred revenue244,638125,000
Accrued expenses173,175-5,691
Operating lease liability-50,511-89,621
Net cash provided by operating activities975,023-158,554
CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds from sale of common stock and exercise of warrants14,800
Repayments on notes payable-206,343-275,106

Statements in this press release about future expectations, plans, and prospects, as well as any other statements regarding matters that are not historical facts, may constitute “forward-looking statements.” These statements include but are not limited to, statements relating to the expected use of proceeds, the Company’s operations and business strategy, and the Company’s expected financial results. The words “anticipate,” “believe,” “continue,” “could,” “estimate,”

“expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,”

“should,” “target,” “will,” “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. The forward-looking statements contained in this press release are based on management’s current expectations and are subject to substantial risks, uncertainty, and changes in circumstances. Investors should read the risk factors set forth in our Form 10-K for the year ended December 31, 2025, and other periodic reports filed with the Securities and Exchange Commission. Any forward-looking statements contained in this press release speak only as of the date hereof, and, except as required by federal securities laws, the Company specifically disclaims any obligation to update any forward-looking statements, whether as a result of new information, future events, or otherwise.

Contact

Christine

Drury

IR/PR

Director

Syra

Health christined@syrahealth.com

463-345-5180

From SEC EDGAR. Analysis by Pear Digitals from the filing alone. Not investment advice. · Syra Health earnings · Latest earnings · Markdown

Screener

Plans

Premium and Pro coming soon.

Log in

New here?

Join the waitlist

Pear FMV opens to everyone soon. We'll email you when it does.